Share this article on:

iPad Extra: Next Steps for Sorafenib in RAI-Refractory DTC

doi: 10.1097/01.COT.0000435377.89374.6f

Get the iPad edition of this issue to listen to additional key thyroid cancer news from the ASCO Annual Meeting. Download the Sept. 25 FOCUS: Thyroid Cancer Supplement iPad issue to hear OT reporter Dan Keller's video interview with:

Figure. No caption a...

Marcia S. Brose, MD, PhD, Assistant Professor of Otolaryngology and Head and Neck Surgery at Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania, who discusses the results of the DECISION trial and the next steps of the research. The data, reported at the Plenary Session, showed that the multi-targeted drug sorafenib extends progression-free survival for patients with differentiated thyroid cancer that is resistant to standard radioiodine therapy—making it the first drug to demonstrate efficacy of any agent for this type of thyroid cancer.

To receive our iPad issues, download the free Oncology Times app from the App Store from, search in the App Store, or follow the link on

Figure. No caption a...
Figure. No caption a...
© 2013 by Lippincott Williams & Wilkins, Inc.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!